Released Mar 2, 2020, after the close
10-K filed Mar 2, 2020, 62 days after period end · 0001564590-20-008141
Q4 2019 · 10-K
Revenue$2.80M$2.80M +68.7% vs Q4 2018+15.4% vs Q3 2019
Net Income-$28.30M-$28.30M N/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.37-$0.37 N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$29,078,000N/M
Operating Cash Flowderived-$25,535,000N/M
Free Cash Flowderived-$28,125,000N/M
Margins · derived
Operating margin-1037.8%−29.9 pt vs Q4 2018
Net margin-1010.1%−45.2 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019 | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $2.80M | $1.66M | $1.03M | $1.03M |
| Net Income | -$28.30M | -$16.03M | -$12.50M | -$7.94M |
| EPS Diluted | -$0.37 | -$0.25 | -$0.29 | -$0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR